Dr. Jason R. Hochreiter OD

Recommended Articles

• See How This Police Department Is Trained to Interact with Alzheimer's Patients

  In Little Rock, Arkansas, a police department has added a little more training when handling Alzheimer's patients. In the communities that surround this police department, there are up to 60,000 cases of Alzheimer's disease that have been reported. Because of this training, the Little Rock Police...

• New Test of Mucus Properties May Help with Coughing and Airway Clearance in CF

  In the United States, there are currently 30,000 individuals living with cystic fibrosis - a progressive, hereditary condition that results in persistent lung infections and airway obstruction, making it difficult to breathe. There is no cure for cystic fibrosis, although there are several treatment...

• What is the Best Diet Plan for Ulcerative Colitis?

  Ulcerative colitis is a chronic disease characterized by inflammation and ulcer formation in the lining of the large intestine, including the colon and rectum. This condition together with other diseases of the large intestine, like Crohn’s disease, is referred to inflammatory bowel disease. These...

• Sore Tongue

  The tongue is made up of different muscles that help us speak, swallow, chew, or taste food. So when we have a sore tongue, it can be quite hard to ignore.Although a sore tongue is not always a cause for concern, emergency medical attention may be required in some cases, such as rapid tongue...

• Gas, Bloating, and Burping

  Gas, bloating, and burping are normal conditions that are often very uncomfortable and embarrassing. Gas is produced in the gastrointestinal system as the food is digested to form energy. Changes in the diet can definitely cut down the formation of gas and save you from discomfort and embarrassment....

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...